EDMONTON, ALBERTA--(CCNMatthews - Aug. 10, 2006) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for solid tumors, today announced its financial and operational results for the second quarter and six month period ended June 30, 2006.
